Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions.
Extranodal marginal zone B-cell lymphoma (EMZL), also known as mucosa-associated lymphoid tissue (MALT) lymphoma, is a rare type of non-Hodgkin lymphoma that originates in the marginal zone B cells outside of the lymph nodes. It often develops in various extranodal sites of the body, particularly mucosal tissues such as the stomach, salivary glands, lungs, thyroid, and other organs.
MALT lymphoma represents a small percentage of non-Hodgkin lymphomas. It is most diagnosed in adults, with a median age at diagnosis typically in the 60s, although it can occur at any age. MALT lymphoma often arises due to chronic inflammation or immune responses in specific tissues, leading to the proliferation of marginal zone B cells. In many cases, it is associated with chronic infections or autoimmune disorders that trigger persistent antigen stimulation, such as Helicobacter pylori infection in gastric MALT lymphoma or Sjögren’s syndrome in salivary gland MALT lymphoma.
The Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) drugs in development market research report provide comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 47 molecules, with 41 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAmgen Inc
Antengene Corp Ltd
AstraZeneca Plc
Aurigene Oncology Ltd
BeiGene Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
BioIntegrator
Bristol-Myers Squibb Co
CoImmune Inc
Cullinan Oncology Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
F. Hoffmann-La Roche Ltd
Fosun Pharma Kite Biotechnology Co Ltd
General Hospital of the People's Liberation Army
Genmab AS
Gilead Sciences Inc
Hebei Senlang Biotechnology Co Ltd
Hutchison MediPharma Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Massachusetts General Hospital
Mayo Clinic
Medical College of Wisconsin
MorphoSys AG
Nanjing Sanhome Pharmaceutical Co Ltd
Oncternal Therapeutics
Qilu Puget Sound Biotherapeutics Corp
Secura Bio Inc
SELLAS Life Sciences Group Inc
Shanghai Henlius Biotech Inc
Swedish Orphan Biovitrum AB
SymBio Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
UNC Lineberger Comprehensive Cancer Center
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions